Page 2 - ஒட்டு எதிராக தொகுப்பாளர் நோய் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Press release content from Business Wire. The AP news staff was not involved in its creation. ASC Therapeutics Receives IND Clearance From the U.S. Food and Drug Administration for ASC618 Second-Generation Gene Therapy for Hemophilia A July 8, 2021 GMT MILPITAS, Calif. (BUSINESS WIRE) Jul 7, 2021 ASC Therapeutics, a privately-held biopharmaceutical company pioneering the development of transformative in-vivo gene replacement, gene editing and allogeneic cell therapies for hematologic and other rare disorders today announced that the U.S. Food & Drug Administration (FDA) has cleared an Investigational New Drug (IND) application for ASC618, an investigational second-generation gene therapy for patients with severe and moderately severe hemophilia A. The transformational Adeno-Associated Virus (AAV) construct contains a proprietary B-domain deleted codon-optimized bioengineered chimeric Factor VIII (FVIII) gene and a minimal-length liver-specific promoter, shown in pre-clinical stu

United statesRuhong jiangOscar seguradoPreclinical developmentUs food drug administrationTherapeutics incEmory universityUniversity of michiganDrug administrationInvestigational new drugAdeno associated virusExpression therapeuticsOrphan drug designationDecidua stromal cell basedGraft versus host diseasePrivate securities litigation reform act